• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

天然产物作为胰腺癌 细胞增殖和侵袭的抑制剂:可能的机制

Natural products as inhibitors against pancreatic cancer cell proliferation and invasion: possible mechanisms.

作者信息

Li Xiang, Yang Xu, Guo Wei, Li Hao, Sun Weiqing, Lin Xingda, Ma Zuoxin, Li Xuan, Liu Zhe

机构信息

Department of Pancreatic-Biliary Surgery, The First Hospital of China Medical University Shenyang 110001, Liaoning, China.

Medical Laboratory, Liaoning Province Hospital Shenyang 110001, Liaoning, China.

出版信息

Am J Cancer Res. 2024 Jun 15;14(6):2695-2713. doi: 10.62347/XLZX8935. eCollection 2024.

DOI:10.62347/XLZX8935
PMID:39005683
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11236794/
Abstract

Pancreatic cancer is one of the gastrointestinal tumors with the lowest survival rate and the worst prognosis. At the time of diagnosis, the majority of patients have missed the opportunity for radical surgical resection and opt for chemotherapy as their primary treatment choice. And drug resistance emerges during the application of the most widely used chemotherapeutic regimens such as modified FOLFIRINOX regimen, gemcitabine monotherapy or 5-Fluorouracil combination therapy, which further reduces the therapeutic efficacy. Therefore, it is urgent to explore better treatment strategies for pancreatic cancer. In recent years, more and more studies have found that natural products have significant anti-pancreatic cancer properties. In this paper, we reviewed the possible mechanisms by which natural products inhibit the proliferation and invasion of pancreatic cancer cells, including the possible mechanisms of targeting the inhibition of the growth and proliferation regulatory pathways of pancreatic cancer cells, inducing apoptosis and autophagy of pancreatic cancer cells, inhibiting the EMT process of pancreatic cancer cells, and inhibiting the angiogenesis of pancreatic cancer. Meanwhile, natural products have also hindered the progress of their basic and clinical research due to the complexity of their composition and the limitation of biological extraction technology. Further exploration of the specific molecular mechanisms of natural products to inhibit the proliferation and invasion of pancreatic cancer cells, optimization of purification and preparation techniques, and enrichment of basic and clinical trials to verify their efficacy and safety may be the future direction of natural products in the field of anti-pancreatic cancer research.

摘要

胰腺癌是生存率最低、预后最差的胃肠道肿瘤之一。在确诊时,大多数患者已错过根治性手术切除的机会,而选择化疗作为主要治疗手段。并且在应用最广泛的化疗方案(如改良FOLFIRINOX方案、吉西他滨单药治疗或5-氟尿嘧啶联合治疗)过程中会出现耐药性,这进一步降低了治疗效果。因此,迫切需要探索更好的胰腺癌治疗策略。近年来,越来越多的研究发现天然产物具有显著的抗胰腺癌特性。本文综述了天然产物抑制胰腺癌细胞增殖和侵袭的可能机制,包括靶向抑制胰腺癌细胞生长和增殖调控途径、诱导胰腺癌细胞凋亡和自噬、抑制胰腺癌细胞的上皮-间质转化过程以及抑制胰腺癌血管生成的可能机制。同时,由于天然产物成分复杂以及生物提取技术的限制,其基础和临床研究进展也受到了阻碍。进一步探索天然产物抑制胰腺癌细胞增殖和侵袭的具体分子机制、优化纯化和制备技术、丰富基础和临床试验以验证其疗效和安全性,可能是天然产物在抗胰腺癌研究领域的未来发展方向。

相似文献

1
Natural products as inhibitors against pancreatic cancer cell proliferation and invasion: possible mechanisms.天然产物作为胰腺癌 细胞增殖和侵袭的抑制剂:可能的机制
Am J Cancer Res. 2024 Jun 15;14(6):2695-2713. doi: 10.62347/XLZX8935. eCollection 2024.
2
Selecting chemotherapy for pancreatic cancer: Far away or so close?选择胰腺癌化疗:远在天边还是近在咫尺?
Semin Oncol. 2019 Feb;46(1):39-47. doi: 10.1053/j.seminoncol.2018.12.004. Epub 2018 Dec 27.
3
Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.新辅助FOLFIRINOX方案与直接手术治疗可切除胰头癌的比较(NORPACT-1):一项多中心、随机、2期试验
Lancet Gastroenterol Hepatol. 2024 Mar;9(3):205-217. doi: 10.1016/S2468-1253(23)00405-3. Epub 2024 Jan 15.
4
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.白蛋白结合型紫杉醇联合吉西他滨对比白蛋白结合型紫杉醇联合吉西他滨序贯 FOLFIRINOX 诱导化疗治疗局部晚期胰腺癌(NEOLAP-AIO-PAK-0113):一项多中心、随机、Ⅱ期临床试验。
Lancet Gastroenterol Hepatol. 2021 Feb;6(2):128-138. doi: 10.1016/S2468-1253(20)30330-7. Epub 2020 Dec 16.
5
The marine natural product Scalarin inhibits the receptor for advanced glycation end products (RAGE) and autophagy in the PANC-1 and MIA PaCa-2 pancreatic cancer cell lines.海洋天然产物 Scalarin 可抑制 PANC-1 和 MIA PaCa-2 胰腺癌细胞系中晚期糖基化终产物受体 (RAGE) 和自噬。
Invest New Drugs. 2019 Apr;37(2):262-270. doi: 10.1007/s10637-018-0635-4. Epub 2018 Jul 12.
6
Use of herbal medicines and natural products: an alternative approach to overcoming the apoptotic resistance of pancreatic cancer.草药和天然产物的应用:克服胰腺癌凋亡抗性的一种替代方法。
Int J Biochem Cell Biol. 2014 Aug;53:224-36. doi: 10.1016/j.biocel.2014.05.021. Epub 2014 May 27.
7
Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study.FOLFIRINOX 和吉西他滨/白蛋白紫杉醇联合序贯治疗晚期胰腺癌患者:一项单中心回顾性队列研究。
Oncol Res Treat. 2022;45(3):79-87. doi: 10.1159/000521258. Epub 2021 Dec 7.
8
Isocorydine decrease gemcitabine-resistance by inhibiting epithelial-mesenchymal transition via STAT3 in pancreatic cancer cells.异紫堇定通过抑制STAT3介导的上皮-间质转化降低胰腺癌细胞对吉西他滨的耐药性。
Am J Transl Res. 2020 Jul 15;12(7):3702-3714. eCollection 2020.
9
Natural Products for Pancreatic Cancer Treatment: From Traditional Medicine to Modern Drug Discovery.天然产物在胰腺癌治疗中的应用:从传统医学到现代药物发现。
Nutrients. 2021 Oct 26;13(11):3801. doi: 10.3390/nu13113801.
10
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.FOLFIRINOX 或吉西他滨作为胰腺癌的辅助治疗。
N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775.

引用本文的文献

1
Harnessing the Therapeutic Potential of Pomegranate Peel-Derived Bioactive Compounds in Pancreatic Cancer: A Computational Approach.利用石榴皮衍生生物活性化合物在胰腺癌中的治疗潜力:一种计算方法。
Pharmaceuticals (Basel). 2025 Jun 15;18(6):896. doi: 10.3390/ph18060896.
2
Oleocanthal as a Multifunctional Anti-Cancer Agent: Mechanistic Insights, Advanced Delivery Strategies, and Synergies for Precision Oncology.油橄榄苦素作为一种多功能抗癌剂:作用机制见解、先进递送策略及精准肿瘤学中的协同作用
Int J Mol Sci. 2025 Jun 9;26(12):5521. doi: 10.3390/ijms26125521.

本文引用的文献

1
Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015).吉西他滨联合纳米白蛋白结合型紫杉醇对比吉西他滨联合S-1作为可切除及临界可切除胰腺导管腺癌新辅助化疗的随机临床研究结果(RCT,CSGO-HBP-015)
Ann Surg Oncol. 2024 Jul;31(7):4621-4633. doi: 10.1245/s10434-024-15199-8. Epub 2024 Mar 28.
2
Efficacy of adding levofloxacin to gemcitabine and nanoparticle-albumin-binding paclitaxel combination therapy in patients with advanced pancreatic cancer: study protocol for a multicenter, randomized phase 2 trial (T-CORE2201).在晚期胰腺癌患者中联合应用左氧氟沙星、吉西他滨和白蛋白结合型紫杉醇的疗效:一项多中心、随机、2 期试验(T-CORE2201)的研究方案。
BMC Cancer. 2024 Feb 24;24(1):262. doi: 10.1186/s12885-024-11973-9.
3
Robinin inhibits pancreatic cancer cell proliferation, EMT and inflammation via regulating TLR2-PI3k-AKT signaling pathway.刺槐素通过调节TLR2-PI3k-AKT信号通路抑制胰腺癌细胞增殖、上皮-间质转化和炎症反应。
Cancer Cell Int. 2023 Dec 18;23(1):328. doi: 10.1186/s12935-023-03167-3.
4
Therapeutic Strategies for Pancreatic-Cancer-Related Type 2 Diabetes Centered around Natural Products.以天然产物为中心的胰腺癌相关 2 型糖尿病治疗策略。
Int J Mol Sci. 2023 Nov 2;24(21):15906. doi: 10.3390/ijms242115906.
5
Targeting HSP70 chaperones by rhein sensitizes liver cancer to artemisinin derivatives.大黄酸靶向热休克蛋白70(HSP70)伴侣蛋白可使肝癌对青蒿素衍生物敏感。
Phytomedicine. 2024 Jan;122:155156. doi: 10.1016/j.phymed.2023.155156. Epub 2023 Oct 20.
6
FOXQ1 promotes pancreatic cancer cell proliferation, tumor stemness, invasion and metastasis through regulation of LDHA-mediated aerobic glycolysis.FOXQ1 通过调节 LDHA 介导的有氧糖酵解促进胰腺癌细胞增殖、肿瘤干性、侵袭和转移。
Cell Death Dis. 2023 Oct 24;14(10):699. doi: 10.1038/s41419-023-06207-y.
7
Nuclear GRP78 Promotes Metabolic Reprogramming and Therapeutic Resistance in Pancreatic Ductal Adenocarcinoma.核 GRP78 促进胰腺导管腺癌的代谢重编程和治疗抵抗。
Clin Cancer Res. 2023 Dec 15;29(24):5183-5195. doi: 10.1158/1078-0432.CCR-23-1143.
8
Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems.基于纳米的药物递送系统在胰腺癌治疗中的进展
Pharmaceutics. 2023 Sep 21;15(9):2363. doi: 10.3390/pharmaceutics15092363.
9
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.NALIRIFOX 对比 nab-紫杉醇和吉西他滨用于治疗初治转移性胰腺导管腺癌(NAPOLI 3):一项随机、开放标签、3 期临床试验。
Lancet. 2023 Oct 7;402(10409):1272-1281. doi: 10.1016/S0140-6736(23)01366-1. Epub 2023 Sep 11.
10
STAT3 inhibition enhances gemcitabine sensitivity in pancreatic cancer by suppressing EMT, immune escape and inducing oxidative stress damage.STAT3 抑制通过抑制 EMT、免疫逃避和诱导氧化应激损伤来增强胰腺癌对吉西他滨的敏感性。
Int Immunopharmacol. 2023 Oct;123:110709. doi: 10.1016/j.intimp.2023.110709. Epub 2023 Jul 27.